
The Health AI Brief
AI For Mammography Screening - Results of Lancet RCT
Will AI replace radiologists? The Lancet just published the final results of the MASAI trial, providing a definitive answer on AI safety in breast cancer screening. We analyse the Gommers et al. (2026) MASAI study, the first randomized controlled trial to prove that AI-supported mammography triage is non-inferior to human double-reading regarding interval cancer rates. The study demonstrates a 44% reduction in workload while significantly increasing screening sensitivity. Link to paper: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00092-9/fulltext Link to comment: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02464-X/fulltext Key Takeaways: โข Safety Proven: AI-supported screening met non-inferiority margins for interval cancer rates (1.55 vs 1.76 per 1000). โข Efficiency Gains: AI triage enabled a 44% reduction in radiologist screen-reading workload. โข Superior Sensitivity: The AI-supported group caught more invasive cancers (80.5% sensitivity) without increasing false positives. AI mammography, MASAI study results, Lancet breast cancer AI, radiologist workforce shortage, interval cancer rate, Transpara AI, breast cancer screening sensitivity, health AI implementation, double reading mammography. #HealthAI #Radiology #BreastCancer #MedTech #TheHealthAIBrief #LancetMedical #aiinmedicine Music generated by Mubert https://mubert.com/render healthaibrief@outlook.com

